Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2013

01-04-2013 | Original Article

Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma

Authors: Silvia Fuertes, Xavier Setoain, Armando Lopez-Guillermo, Josep-Lluis Carrasco, Sonia Rodríguez, Jordina Rovira, Francesca Pons

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2013

Login to get access

Abstract

Purpose

Interim 18F-FDG PET performed early during the course of therapy in diffuse large B-cell lymphoma (DLBCL) is a good predictor of outcome. However, interpretation criteria for interim PET for the evaluation of tumour response are still not clearly defined. The study aim was to assess whether interim PET can predict overall survival (OS) and progression-free survival (PFS) in DLBCL patients following three different sets of parameters, two qualitative (visual) methods and one semiquantitative.

Methods

A total of 50 newly diagnosed DLBCL patients were prospectively enrolled in this study. All patients had a PET/CT scan at diagnosis and an interim PET/CT scan after the second or third cycle of chemotherapy. Three methods of evaluation for the interim PET/CT were used: a qualitative three-point scoring (3-PS) method, a qualitative 5-PS method and a semiquantitative method (ΔSUVmax). The degree of correlation between therapy response seen on FDG PET and PFS and OS was determined.

Results

The analysis of the visual 3-PS method showed no statistically significant difference in PFS and OS. The estimated 5-year PFS and OS were 79 % and 92 %, respectively, in patients with an interim PET scan showing uptake not greater than in the liver versus 50 % in patients with uptake greater than in the liver, and this difference was statistically significant. The optimal cut-off value of ΔSUVmax that could predict the PFS and OS difference in patients with DLBCL was 76 % (95 % CI 62.7–89.2 %) and 75 % (95 % CI, 54.6–95.4 %), respectively.

Conclusion

Our results support the use of liver uptake as an indicator in the qualitative evaluation of interim PET, or a ΔSUVmax greater than 75 % in semiquantitative analysis. Interim PET may predict PFS and OS and could be considered in the prognostic evaluation of DLBCL.
Literature
1.
2.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–26.PubMedCrossRef
3.
Meignan M, Itti E, Gallamini A, Haioun C. Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand? Leuk Lymphoma. 2009;50:1753–6.PubMedCrossRef
4.
Meignan M, Gallamini A, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in lymphoma. Leuk Lymphoma. 2010;51:2171–80.PubMedCrossRef
5.
Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2002;13:1356–63.PubMedCrossRef
6.
Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Barlett NL. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of International Harmonization Project interpretation. J Nucl Med. 2011;52:386–92.PubMedCrossRef
7.
Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160–8.PubMedCrossRef
8.
Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, et al. Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;23:4652–61.PubMedCrossRef
9.
10.
Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119:2066–73.PubMedCrossRef
11.
Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896–903.PubMedCrossRef
12.
Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50:1257–60.PubMedCrossRef
13.
Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European centers of PET reporting criteria designed for use in multicenter trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824–33.PubMedCrossRef
14.
Meignan M. Interim PET in lymphoma: a step towards standardization. Eur J Nucl Med Mol Imaging. 2010;37:1821–3.PubMedCrossRef
15.
Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527–33.PubMedCrossRef
16.
Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma. SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626–32.PubMedCrossRef
17.
Boellard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50:11S–20.CrossRef
18.
Lee ET, Wang JW. Statistical methods for survival data analysis. New York: Wiley; 2003.CrossRef
19.
Skaltsa K, Jover L, Carrasco JL. Estimation of the diagnostic threshold accounting for decision costs and sampling uncertainty. Biom J. 2010;52:676–97.PubMedCrossRef
20.
Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376–81.PubMedCrossRef
21.
Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514–23.PubMedCrossRef
22.
Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma: comparison with CT. Leuk Lymphoma. 2000;39:543–53.PubMedCrossRef
23.
Dührsen U, Hüttmann A, Jöckel KH, Müller S. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphoma – the PETAL trial. Leuk Lymphoma. 2009;50:1757–60.PubMedCrossRef
24.
Deok-Hwan Y, Byun Byung H,-Jung-Joon M, Jae-Sook A, Yeo-Kyeoung K, Hee-Seung B, et al. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in post-rituximab era. 3rd International Workshop on interim PET in lymphoma. 26–27 September 2011, Menton. Abstract.
25.
Lanic H, Mareschal S, Mechken F, Picquenot JM, Bertrand P, Ruminy P, et al. Gene Expression profile and interim TEP scan are two complementary and independent tools to predict the outcome of DLBCL. 3rd International Workshop on interim PET in lymphoma. 26–27 September 2011, Menton. Abstract.
Metadata
Title
Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma
Authors
Silvia Fuertes
Xavier Setoain
Armando Lopez-Guillermo
Josep-Lluis Carrasco
Sonia Rodríguez
Jordina Rovira
Francesca Pons
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2320-8

Other articles of this Issue 4/2013

European Journal of Nuclear Medicine and Molecular Imaging 4/2013 Go to the issue

Original Article

68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT

Original Article

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

Review Article

Value of 11C-methionine PET in imaging brain tumours and metastases

Original Article

Influence of myocardial region of interest definition on quantitative analysis of planar 123I-mIBG images

Original Article

Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database

Original Article

Detection of infarct size safety threshold for left ventricular ejection fraction impairment in acute myocardial infarction successfully treated with primary percutaneous coronary intervention